Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Shell PLC (SHEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Shell PLC — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while Shell PLC trades at $84.79 (market cap $230.24B). The key difference: Shell PLC is far larger — about 28.6× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Shell PLC pays a 3.7% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | SHEL | |
|---|---|---|
Market Cap | $8.04B | $230.24B |
Sector | Health | Energy |
52-Week High | $339.75 | $94.15 |
52-Week Low | $241.71 | $70.28 |
Enterprise Value | $7.85B | $282.77B |
Dividend Yield | — | 3.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
Shell (SHEL) trades at $83.98, up 2.13% in the last session, with a bullish technical signal and strong analyst consensus. Recent Q1 2026 earnings beat expectations at $2.44 EPS, while Q2 2026 is projected at $2.88. Valuation metrics appear attractive with a P/E of 13.08 and P/S of 0.92. News highlights include the ARC Resources acquisition approval and Venezuela gas field developments, indicating strategic growth initiatives.
The outlook for SHEL is positive, supported by robust cash flows, a 69% buy rating from analysts, and a consensus price target of $122.20. Risks include declining revenue trends from $381.3B in 2022 to $266.9B in 2025 and geopolitical disruptions in Middle East production. Investors may find value in its dividend yield and LNG market exposure, though macroeconomic volatility remains a concern.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Shell PLC
Shell is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.7 million barrels of liquids and 8.7 billion cubic feet of natural gas per day. At year-end 2021, reserves stood at 9.2 billion barrels of oil equivalent, 50% of which consisted of liquids. Its production and reserves are in Europe, Asia, Oceania, Africa, and North and South America. The company operates refineries with capacity of 1.8 mmb/d located in the Americas, Asia, Africa, and Europe and sells 15 mtpa of chemicals. Its largest chemical plants, often integrated with its local refineries, are in Central Europe, China, Singapore, and North America.
Read more on SHEL →
